Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Traumatic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    412 result(s) found for: Traumatic. Displaying page 21 of 21.
    «« First « Previous 13  14  15  16  17  18  19  20  21 
    EudraCT Number: 2005-000411-10 Sponsor Protocol Number: 4478944789 Start Date*: Information not available in EudraCT
    Sponsor Name:BG-Kliniken Bergmannsheil, Dept. of Pain Management
    Full Title: Effects of Pregabalin on mechanical hyperalgesia - EPOM
    Medical condition: patients with pain for at least 6 months and hyperalgesia with one of the following diagnoses: peripheral nerve lesion, plexus lesion, radicular lesion, spinal lesion, polyneuropathy, postzosteric ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036105 Polyneuropathy LLT
    9.1 10036105 Polyneuropathy PT
    9.1 10036378 Postherpetic trigeminal neuralgia LLT
    9.1 10064334 Complex regional pain syndrome Type I LLT
    9.1 10064335 Complex regional pain syndrome Type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002935-27 Sponsor Protocol Number: ADVL1712 Start Date*: 2021-05-21
    Sponsor Name:National Cancer Institute
    Full Title: A Feasibility Trial of MLN4924 (Pevonedistat,TAK924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute...
    Medical condition: This trial studies the side effects and how well pevonedistat, azacitidine, fludarabine phosphate, and cytarabine work in treating patients with acute myeloid leukemia that has come back or has not...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024330 Leukemia acute LLT
    21.0 100000004864 10024349 Leukemia myeloid LLT
    21.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004455-36 Sponsor Protocol Number: NP28673 Start Date*: 2013-04-11
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT
    Medical condition: ALK-mutated Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) NL (Completed) BE (Completed) FR (Completed) DK (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2006-004779-36 Sponsor Protocol Number: BMTI-2006-03-EU Start Date*: 2007-01-22
    Sponsor Name:BioMimetic Therapeutic Inc
    Full Title: A Human Clinical Trial to Evaluate the Safety and Clinical Utility of GEM OS1 as a Bone Regeneration System in Foot and Ankle Arthrodesis Procedures
    Medical condition: For use as a bone void filler for voids or gaps that are not intrinsic to the stability of bony structure. Treatment of surgically created osseous defects or osseous defects resulting from patholo...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061683 Arthrodesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000748-32 Sponsor Protocol Number: SPI-62-CL-2002 Start Date*: 2023-08-29
    Sponsor Name:Sparrow Pharmaceuticals, Inc.
    Full Title: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
    Medical condition: Hypercortisolism Related to a Benign Adrenal Tumor
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004860 10020611 Hypercortisolism LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006342-32 Sponsor Protocol Number: 75111-10114 Start Date*: 2013-06-11
    Sponsor Name:EORTC
    Full Title: Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression whi...
    Medical condition: Newly diagnosed or recurrent (after surgery) stage IV (TNM/AJCC v.7) HER-2 positive (IHC 3+ or or HER-2 gene amplification by in situ hybridization) invasive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Completed) PT (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004305-40 Sponsor Protocol Number: CSL222-3001 Start Date*: 2018-10-12
    Sponsor Name:CSL Behring LLC
    Full Title: Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene ...
    Medical condition: Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006067-28 Sponsor Protocol Number: CST103/CST107-CLIN-011 Start Date*: 2022-01-10
    Sponsor Name:CuraSen Therapeutics, Inc.
    Full Title: A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 co-administered with CST-107 on the Central Nervous System in Subjects with Neur...
    Medical condition: Patients with Parkinson’s Disease with REM sleep behaviour disorder, Mild Cognitive Impairment, Dementia with Lewy Bodies and Parkinson’s Disease Dementia.
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029205 - Nervous system disorders 10012284 Dementia due to Parkinson's disease LLT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    21.1 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    20.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001521-25 Sponsor Protocol Number: NEOMERO-2 Start Date*: 2011-12-15
    Sponsor Name:FONDAZIONE PENTA ONLUS
    Full Title: Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: a European multicenter phase II trial
    Medical condition: Bacterial meningitis in children up to 90 days of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10004049 Bacterial meningitis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed) NL (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000520-15 Sponsor Protocol Number: B1821010 Start Date*: 2011-09-29
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTICENTER, OPEN LABEL STUDY TO COMPARE ON DEMAND TREATMENT TO A PROPHYLAXIS REGIMEN OF NONACOG ALFA (BENEFIX) IN SUBJECTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B (FIX:C ≤2%)
    Medical condition: Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    15.0 10010331 - Congenital, familial and genetic disorders 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: PL (Completed) BG (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-003148-51 Sponsor Protocol Number: F13CD-1725 Start Date*: 2008-08-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII ...
    Medical condition: Congenital Factor XIII Deficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010432 Congenital deficiency of other clotting factors LLT
    9.1 10061992 Haemophilia LLT
    9.1 10009735 Coagulation disorders congenital HLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) AT (Completed) ES (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003895-35 Sponsor Protocol Number: D4280C00005 Start Date*: 2012-04-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole V...
    Medical condition: Complicated Intra-Abdominal Infection (cIAI)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) GR (Completed) ES (Completed) BG (Completed) IT (Completed) LT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 13  14  15  16  17  18  19  20  21 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 17:09:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA